Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
Public ClinicalTrials.gov record NCT05298423. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab.
Study identification
- NCT ID
- NCT05298423
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 610 participants
Conditions and interventions
Conditions
Interventions
- pembrolizumab/vibostolimab Biological
- durvalumab Biological
- cisplatin Drug
- pemetrexed Drug
- etoposide Drug
- carboplatin Drug
- paclitaxel Drug
- thoracic radiotherapy Radiation
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 3, 2022 (Actual)
- Primary completion
- Jun 15, 2026 (Actual)
- Completion
- Jun 15, 2026 (Actual)
- Last update posted
- Aug 28, 2026
2022 – 2026
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| VA Long Beach Healthcare System ( Site 2831) | Long Beach | California | 90822 | — |
| VA West Los Angeles Medical Center ( Site 2808) | Los Angeles | California | 90073 | — |
| Millennium Oncology Research Clinic ( Site 2801) | Hollywood | Florida | 33024 | — |
| Mid Florida Hematology and Oncology Center ( Site 2800) | Orange City | Florida | 32763 | — |
| Moffitt Cancer Center ( Site 2818) | Tampa | Florida | 33612 | — |
| University of Chicago Medical Center ( Site 2828) | Chicago | Illinois | 60637 | — |
| Franciscan St. Francis Health ( Site 2812) | Indianapolis | Indiana | 46237 | — |
| MFSMC-HJWCI ( Site 2804) | Baltimore | Maryland | 21237 | — |
| Boston Medical Center ( Site 2829) | Boston | Massachusetts | 02118 | — |
| University of Massachusetts Chan Medical School ( Site 2815) | Worcester | Massachusetts | 01655 | — |
| University of Missouri Hospital ( Site 2839) | Columbia | Missouri | 65212 | — |
| Cox Medical Center North-Cox Medical Center/Hulston Cancer Center/ Radiation Oncology ( Site 2837) | Springfield | Missouri | 65807 | — |
| Rutgers Cancer Institute of New Jersey ( Site 2805) | New Brunswick | New Jersey | 08901 | — |
| Icahn School of Medicine at Mount Sinai ( Site 2821) | New York | New York | 10029 | — |
| White Plains Hospital ( Site 2835) | White Plains | New York | 10601 | — |
| Kaiser Permanente Northwest-Central Interstate--Oncology ( Site 2816) | Portland | Oregon | 97227 | — |
| Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 2827) | Lancaster | Pennsylvania | 17601 | — |
| Thomas Jefferson University - Clinical Research Institute ( Site 2813) | Philadelphia | Pennsylvania | 19107 | — |
| Millennium Research & Clinical Development ( Site 2811) | Houston | Texas | 77090 | — |
| Central Texas Veterans health care-Oncology & Hematology ( Site 2819) | Temple | Texas | 76504 | — |
| MultiCare Health System ( Site 2817) | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 139 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05298423, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05298423 live on ClinicalTrials.gov.